Issue: December 2019

Read more

October 17, 2019
3 min read
Save

Hydroxychloroquine Blood Levels Predict Retinopathy in SLE

Issue: December 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Michelle Petri, MD, MPH
Michelle Petri

Increased hydroxychloroquine blood levels can be used to predict later hydroxychloroquine retinopathy, according to findings published in Arthritis & Rheumatology.

Perspective from Barry L. Gruber, MD

“The American Academy of Ophthalmology (AAO) 2011 recommendations advised hydroxychloroquine weight-based dosing of 6.5 mg/kg with a maximum dose of 400 mg/day,” Michelle Petri, MD, MPH, of the Johns Hopkins University School of Medicine, and colleagues wrote. “[However,] a retrospective review of 2,361 Kaiser Permanente patients who had used hydroxychloroquine, reported toxicity at 5 years in under 1%, up to 10 years in under 2%, but almost 20% after 20 years.”

“This led, in 2016, to revised AAO recommendations that the maximum daily hydroxychloroquine should be less than 5.0 mg/kg real weight, which they thought might correlate better with risk than ideal weight,” they added. “These dosing recommendations were made without evidence that the lower dose of hydroxychloroquine would have the same efficacy for SLE activity or the same protective role against cardiovascular risk factors and thrombosis.”

To analyze the frequency of hydroxychloroquine retinopathy, as well as the ability of hydroxychloroquine blood levels to predict retinopathy risk, Petri and colleagues conducted a study of 537 patients with systemic lupus erythematosus from the Hopkins Lupus Cohort. The researchers assessed patients for hydroxychloroquine blood levels and tested for hydroxychloroquine retinopathy at each visit starting in 2013.

For their analysis, hydroxychloroquine toxicity was defined by a retina specialist at the Johns Hopkins Wilmer Eye Institute, who examined participants taking the drug. The researchers assessed the risk for hydroxychloroquine toxicity in tertiles based on the mean or maximum hydroxychloroquine levels in the blood.

According to the researchers, the frequency of retinopathy was 4.3%. Broken down by year, there was a 1% risk for retinopathy during the first 5 years, a 1.8% risk from year 6 to 10, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years and 8% after 21 years of hydroxychloroquine use. In addition, older patients (P < .0001), those with higher BMI (P = .016 for trend) and longer duration of drug intake (P = .0024 and P = .0006 for trend) were associated with a greater risk for hydroxychloroquine toxicity.

The researchers found that higher hydroxychloroquine blood levels predicted later hydroxychloroquine retinopathy (P = .0124 for mean blood levels; and P = .034 for maximum).

“Hydroxychloroquine retinopathy is more common than previously thought, but the frequency slope increases after 15 years, and even for patients on it for 20 years is only about 10%,” Petri told Healio Rheumatology. “The time for therapeutic blood monitoring for hydroxychloroquine has arrived. First, because blood level monitoring can detect patients who are nonadherent and therefore cannot benefit from the benefits of hydroxychloroquine, including improved survival.”

“Also, because patients with the highest tertile are at greatest risk of hydroxychloroquine retinopathy,” she added. “Those patients would have their hydroxychloroquine dose reduced. Blood levels — which are done at Johns Hopkins — are more valid than plasma levels.” – by Jason Laday

Disclosure: The researchers report no relevant financial disclosures.